<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04610814</url>
  </required_header>
  <id_info>
    <org_study_id>2019P003733</org_study_id>
    <nct_id>NCT04610814</nct_id>
  </id_info>
  <brief_title>Blood Transfusion by Boston MedFlight Registry</brief_title>
  <official_title>Blood Transfusion by Boston MedFlight Registry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boston MedFlight</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Boston Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lahey Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beth Israel Deaconess Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary aim of this observational registry is to study the outcomes of patients with&#xD;
      hemorrhagic shock transported by Boston MedFlight receiving blood products during transport.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Boston MedFlight, a critical care transport organization, based on a consortium of the&#xD;
      academic medical centers in Boston, will begin carrying PRBC in 2019. The program is intended&#xD;
      to provide BMF clinicians with 24-hour immediate access to appropriate blood products to be&#xD;
      utilized if needed for patients following life-threatening illness or injury. The four&#xD;
      fundamental goals of this program are: save lives' ensure transfusion safety; minimize blood&#xD;
      product waste; and conduct continuous quality assurance. Our goal is to observationally&#xD;
      evaluate this new protocol of administering blood products in the pre-hospital setting. We&#xD;
      will collect data on patients with hemorrhagic shock being transported by Boston MedFlight,&#xD;
      who receive or would have been eligible to receive pre-hospital blood transfusion by the&#xD;
      inclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 1, 2019</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>30 Days</target_duration>
  <primary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30 days</time_frame>
    <description>30-day all cause mortality</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Hemorrhagic Shock</condition>
  <arm_group>
    <arm_group_label>Blood products during transport</arm_group_label>
    <description>Administration of appropriate blood products during transport</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <description>Receiving standard prehospital air medical care</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Any patient being transported by Boston MedFlight with hemorrhagic shock&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Adult patients who would be eligible to receive blood products;&#xD;
&#xD;
               -  systolic blood pressure &lt;90 mmHg&#xD;
&#xD;
               -  a shock index of &gt; 0.9&#xD;
&#xD;
               -  clinical signs of shock as determined by the transport clinicians.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Susan R Wilcox, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital and Boston MedFlight</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Angela Renne</last_name>
    <phone>617-643-2440</phone>
    <email>ARENNE@MGH.HARVARD.EDU</email>
  </overall_contact>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan R Wilcox, MD</last_name>
      <phone>617-724-1973</phone>
      <email>SWILCOX1@PARTNERS.ORG</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>October 26, 2020</study_first_submitted>
  <study_first_submitted_qc>October 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Susan Renee Wilcox</investigator_full_name>
    <investigator_title>Chief, Division of Critical Care, Department of Emergency Medicine</investigator_title>
  </responsible_party>
  <keyword>Blood transfusion</keyword>
  <keyword>Pre-hospital care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Hemorrhagic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

